LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Rituximab, interferon‐alfa‐2b and dose dense CVP is highly efficient in patients with FLIPI ≥ 2 follicular lymphoma. Final results of the LNH‐PRO‐05 study

Photo by nci from unsplash

Sarah Davis Steve Goodacre Abdullah Pandor Daniel Horner John W. Stevens Kerstin de Wit Beverley J. Hunt ScHARR, University of Sheffield, Sheffield, UK, Emergency Department, Salford Royal NHS Foundation Trust,… Click to show full abstract

Sarah Davis Steve Goodacre Abdullah Pandor Daniel Horner John W. Stevens Kerstin de Wit Beverley J. Hunt ScHARR, University of Sheffield, Sheffield, UK, Emergency Department, Salford Royal NHS Foundation Trust, Salford, UK, Department of Medicine, Hamilton General Hospital, Hamilton, Canada, and Haemostasis Research Unit, Kings College London, London, UK. E-mail: [email protected]

Keywords: interferon alfa; alfa dose; dense cvp; rituximab interferon; dose dense; cvp highly

Journal Title: British Journal of Haematology
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.